ClinicalTrials.gg
RecruitingNCT06467812Updated Jul 10, 2024

Fluid Loading Countermeasures

An interventional study of Salt Tablets and Electrolyte Solution in Healthy, sponsored by National Aeronautics and Space Administration (NASA). Recruiting at 1 site in United States. Open to participants aged 25 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-10.

Sponsored by National Aeronautics and Space Administration (NASA) · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2024, 2 years 1 month ago, but the record still lists the study as recruiting.
  • Registered 1 year 11 months after the study started (first participant enrolled Apr 2022, registered Mar 2024).
  • Started Apr 2022; still recruiting 4 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
25 Years to 55 Years
Sex
All
01

Study summary

The purpose of Fluid Loading Countermeasures is to determine how the volume of blood and of plasma (liquid part of blood) change during a normal day, how these are affected by drinking an additional amount of fluid either as water and salt tablets (as astronauts do) or an electrolyte beverage (similar to but tastes saltier than Gatorade®), and how altering the timing at which the additional fluid is consumed affects blood and plasma volume. This study observes how blood volume changes over \~9 hours of the day during 4 separate visits in healthy participants. During 1 visit participants will drink a small amount of water throughout the visit. During the other 3 study visits participants will drink the small amount of water plus either more water with salt tablets or an electrolyte solution. Consuming the additional fluids is called "fluid loading". This study is meant to simulate the food and fluid consumption of astronauts on landing day. The goal of this study is to determine the magnitude of plasma volume change that occurs with each condition of the protocol. (ICF 1.1, 3.1)

Read the detailed description

Upon arrival for each visit, participants will be told which study session they will be participating in that day. Food and water consumption as well as fluid loading will be timed throughout the day during other testing described below. Participants will be asked to empty their bladder, and body weight will be measured using a standard calibrated medical scale. Then, an intravenous (IV) catheter (a small plastic tube) will be inserted into a vein in the participant's arm. This IV catheter will remain in their arm for the duration of the study day. This is the same method that is used in a doctor's office or hospital. All blood samples will be obtained using the IV catheter in the arm.

Next, a test called Carbon Monoxide Re-Breathing (CORB) will be done to measure plasma volume, which is the liquid part of blood. A clip will be placed on the participant's nose so that they are breathing only through their mouth. Participants will breathe through a mouthpiece connected to a rebreathing circuit containing 100% oxygen, which is scrubbed by soda lime to remove carbon dioxide. After \~5 minutes, the first blood sample (\~10 Milliliters [mL]) will be collected from an arm vein using the IV catheter. Thereafter, a small amount of carbon monoxide will be added into the breathing circuit, and the participant will breathe this mixture of carbon monoxide and oxygen for \~10 min. Then, a second \~10 mL blood sample will be obtained. Analysis of the blood samples (i.e., hematocrit, hemoglobin, and carboxyhemoglobin) will be used to calculate red blood cell mass, plasma volume, and total blood volume. The total amount of carbon monoxide will be determined based on the participant's body weight (1 mL/kg body mass for men; 0.8 mL/kg body mass for women), and this dose should result in no symptoms. Mild symptoms of carbon monoxide toxicity may occur at carboxyhemoglobin levels >10% but given the dose of carbon monoxide administered in this study, reaching this level is unlikely.

Participants will be seated for the duration of the study, except for short bathroom breaks allowed periodically during the study session. The volume of urine and the time of collection will be measured and recorded throughout the day. Participants will be provided food during the morning as well as water to drink during the first 5 hours of each visit. Meals will be like those typically consumed by astronauts on the International Space Station. During 3 of the visits, participants will be given additional fluids to drink on a set schedule (Fluid Loading). Participants will not be allowed to consume any fluids or food during the last 3.5 hours of the visit. Participants will be asked about the presence of gastrointestinal symptoms periodically throughout each study session. Additionally, we ask that participants report to the PI/study lead if any off-nominal gastrointestinal symptoms occur in the day of the study visit after testing is completed.

During the last 3.5 hours of each visit, 5 additional blood samples will be obtained (one each hour), used to calculate the change in plasma volume at each time point. Participant blood pressure and heart rate will be measured periodically throughout the day. (IRB protocol section 4.0)

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

National Aeronautics and Space Administration (NASA) is the lead sponsor of 14 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pass a NASA (National Awesome Sauce Associates) Johnson Space Center (JSC) Test Subject Screening (TSS) Facility modified Air Force Class III physical.

Exclusion criteria

Exclusion Criteria:

  • Pregnant subjects will be excluded (a urine pregnancy screen will be made available to test subjects)
  • Systemic diseases or current medications known to influence the cardiovascular system
  • Renal disease
  • Type II Diabetes
  • Restrictive diet that would prevent subjects from consuming typical food eaten by astronauts. Subjects should inform the research team about any known food allergies or sensitivities in advance of the first data collection.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • No intervention
    Control

    A typical water and meal schedule will be followed on the Control day.

  • Experimental
    Water plus Salt Tablets

    A typical water and meal schedule will be followed, with the addition of Fluid Loading water plus salt tablets.

    Dietary Supplement: Salt Tablets

  • Experimental
    Electrolyte Solution over 4 hours

    A typical water and meal schedule will be followed, with the addition of Fluid Loading electrolyte solution over 4 hours.

    Dietary Supplement: Electrolyte Solution

  • Experimental
    Electrolyte Solution Single Bolus

    A typical water and meal schedule will be followed, with the addition of Fluid Loading electrolyte solution single bolus.

    Dietary Supplement: Electrolyte Solution

Interventions

  • Dietary supplementSodium ChlorideStudies of Sodium ChlorideSodium Chloride pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Three doses of 4 Salt Tablets (1gm) will be taken with 400mL of water on day 2 (1200ml total) between \~8am and \~12pm during the testing day, which runs from \~7am to \~3:30pm.

  • Dietary supplementElectrolytesStudies of ElectrolytesElectrolytes pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Three doses of 400mL of the Electrolyte Solution dissolved in water (1200 mL total) will be consumed on day 3 between \~8am and \~12pm during the testing day, which runs from \~7am to \~3:30pm. On day 4 the Electrolyte Solution Single Bolus will be consumed in a single dose of 1200mL at \~12pm during the testing day. The ingredients are included below for the two flavors offered. Orange flavor: Water, Dextrose with Maltodextrin, Aspartame, Acesulfame Potassium, Sodium Citrate, Salt, Citric Acid, Maltodextrin, Natural Flavor, Calcium Phosphate, Contains less than 2% Of Ascorbic Acid (Vitamin C), Artificial Flavor, Artificial Color, Red 40, Yellow 5, BHA (Butylated Hydroxyanisole). Lemonade flavor: Water, Dextrose with Maltodextrin, Aspartame, Acesulfame Potassium, Sodium Citrate, Salt, Citric Acid, Calcium Phosphate, Maltodextrin, Contains less than 2% Of Ascorbic Acid (Vitamin C), Natural Flavor, Artificial Color, Yellow 5, BHA.

06

What researchers measure

Primary outcomes

  1. Plasma Volume

    Plasma volume and change in plasma volume is calculated using the Dill and Costill equation cited here: Dill DB, Costill DL. Calculation of percentage changes in volumes of blood, plasma, and red cells in dehydration.

    Time frame: 8-9 hours

  2. Fluid Balance

    Urine output subtracted from fluid intake (mL)

    Time frame: 8-9 hours

  3. Gastrointestinal Distress

    Open response questionnaire self-reported symptoms

    Time frame: 8-9 hours

  4. Urine Volume

    void-by-void urine output collected and measured (mL)

    Time frame: 8-9 hours

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — No plan to share data.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2022 (actual). Primary completion is estimated for Oct 2024, 30 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2024
First posted
Jun 21, 2024
StartActual
Apr 1, 2022
Primary completionEst.
Oct 2024
CompletionEst.
Oct 2024
Last update
Jul 10, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06467812
Lead sponsor
National Aeronautics and Space Administration (NASA)
Responsible party
Sponsor
First posted
Jun 21, 2024
Start date
Apr 1, 2022
Primary completion
Oct 2024 (estimated)
Completion
Oct 2024 (estimated)
Last update
Jul 10, 2024

Study contacts

Jason R. Lytle, PhD
Contact
jason.r.lytle@nasa.gov
805-407-5038
Lucinda M. Yu, MS
Contact
lucinda.m.yu@nasa.gov
Jason R. Lytle, PhD
principal investigator · National Aeronautics and Space Administration (NASA)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sodium Chloride · Electrolytes

Start the discussion